Repair Biotechnologies, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its investigational therapy REP-0003 for the treatment of homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder characterized by severely elevated cholesterol levels and accelerated atherosclerosis.
REP-0003 is a messenger RNA (mRNA) therapy developed using the company's proprietary Cholesterol Degrading Platform (CDP). The therapy is designed to selectively clear harmful excess free cholesterol from cells while preserving essential cholesterol, potentially offering a breakthrough approach for patients with severe atherosclerosis.
"REP-0003 is a cutting-edge messenger RNA therapy that clears harmful excess free cholesterol inside cells while preserving essential cholesterol, a potential breakthrough for the treatment of severe atherosclerosis in HoFH patients," said Mourad Topors, CSO at Repair Biotechnologies.
Promising Preclinical Results
In preclinical studies using LDLR-knockout mouse models of HoFH, REP-0003 has demonstrated significant efficacy. These mice, which lack functional low-density lipoprotein receptors (LDLR) similar to humans with HoFH, typically exhibit impaired cholesterol metabolism and accelerated atherosclerotic plaque formation.
According to Topors, the therapy has "consistently produced sizable regression of atherosclerotic plaque, restored liver function, and improved exercise capacity" in these models. These results suggest potential for meaningful clinical benefits in human patients with this life-threatening condition.
The company's approach targets what has previously been considered an "undruggable target" - toxic excess intracellular cholesterol in tissues - providing a novel mechanism to safely break down and eliminate this harmful accumulation.
Significance of Orphan Drug Designation
The Orphan Drug Designation acknowledges the significant unmet medical need in the HoFH community and provides Repair Biotechnologies with several important benefits:
- Seven years of market exclusivity upon approval for HoFH treatment
- Tax credits for qualified clinical trial expenses
- Exemption from FDA user fees
- Potential access to specialized FDA guidance and fast-track development pathways
"The Orphan Drug Designation is a major milestone for our program, and acknowledges the continued and significant unmet need in the HoFH community," said Reason, Repair Biotechnologies' CEO. "It is an important step forward in our efforts to bring the first potentially curative therapy to the clinic for HoFH patients with severe, life-threatening atherosclerotic plaque."
Understanding HoFH
Homozygous familial hypercholesterolemia is an ultra-rare genetic disorder affecting approximately 1 in 300,000 people. Patients with HoFH have mutations in both copies of the LDLR gene, resulting in extremely high LDL cholesterol levels from birth. This leads to premature and aggressive atherosclerosis, with many patients experiencing cardiovascular events in childhood or early adulthood.
Current treatment options for HoFH include statins, PCSK9 inhibitors, ezetimibe, and LDL apheresis (a dialysis-like procedure to remove LDL from the blood). However, these approaches often provide insufficient cholesterol reduction in HoFH patients, highlighting the need for novel therapeutic strategies.
Development Timeline
Repair Biotechnologies plans to initiate its first clinical trial of REP-0003 in 2026. The company, based in Syracuse, New York, is focused on developing first-in-class therapies capable of rapidly reducing atherosclerotic plaque.
"We are excited by the transformative potential of REP-0003 and look forward to working with the FDA to bring this potentially life-changing treatment to patients," added Topors.
The company's proprietary Cholesterol Degrading Platform represents a novel approach to addressing cholesterol-related disorders and could potentially have applications beyond HoFH in the future.
